Ketoprofen
Administration
- Type: NSAID
- Dosage Forms: Cap 50mg, 75mg; ER Cap 200mg
- Routes of Administration: Oral
- Common Trade Names: Oruvail
Adult Dosing
Pain, mild-moderate
- 50mg PO q6-8h
- Max: 300mg/day
Osteoarthritis
- 75mg PO TID or 50mg PO qid or 200mg ER PO daily
- Max: 300mg/day
Rheumatoid arthritis
- 75mg PO TID or 50mg PO qid or 200mg ER PO daily
- Max: 300mg/day
Dysmenorrhea
- 50mg PO q6-8h
- Max: 300mg/day
Anti-inflammatory uses
- 50-100mg PO TID x7-14 days
- Max: 300mg/day
Pediatric Dosing
- Pediatric safety for this drug has not yet been established
Special Populations
Pregnancy Rating
- Caution advised in 1st trimester for risk of embryo-fetal toxicity
- Avoid use starting at 30 wk gestation for risk of premature fetal ductus arteriosus closure
- Caution advised in female pts trying to conceive
Lactation risk
- Consider alternative while breastfeeding
Renal Dosing
- Adult:
- Mild Impairment: Max 150 mg/day
- CrCl <25: Max 100 mg/day
- HD/PD: No supplement
- Pediatric: Not defined
Hepatic Dosing
- Adult: Max 100 mg/day with hepatic impairment
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- ASA or NSAID-induced asthma or urticaria
- Pregnancy starting at 30wk gestation
- CABG surgery periop use
- Aspirin triad
Adverse Reactions
Serious
- GI bleeding, perforation, ulcer
- MI, Stroke, HTN, CHF
- Thromboembolism
- Renal papillary necrosis, nephrotoxicity, hepatotoxicity
- Bronchospasm
- Stevens-Johnson syndrome, Toxic epidermal necrolysis
- Anemia, blood dyscrasias, prolonged bleeding time
- Hyperkalemia
Common
- Dyspepsia, nausea, abdominal pain
- Constipation
- Headache, dizziness, somnolence
- Rash, peripheral edema, fluid retention
- Tinnitus, photosensitivity
- Ecchymosis
- Delayed ovulation
Pharmacology
- Half-life: 2.1h
- Metabolism: Liver extensively, tissues
- Excretion: Urine 80% (<10% unchanged)
Mechanism of Action
- Inhibits cyclooxygenase, reducing prostaglandin and thromboxane synthesis